Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Aileron Therapeutics

Nasdaq:ALRN
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALRN
Nasdaq
$9M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Aileron Therapeutics has significant price volatility in the past 3 months.
ALRN Share Price and Events
7 Day Returns
-13.2%
NasdaqCM:ALRN
2%
US Biotechs
-2.8%
US Market
1 Year Returns
-82.4%
NasdaqCM:ALRN
-1.3%
US Biotechs
-15.9%
US Market
ALRN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aileron Therapeutics (ALRN) -13.2% -44.1% -51.7% -82.4% - -
US Biotechs 2% -8% -4.6% -1.3% 10.5% -12%
US Market -2.8% -18.8% -24% -15.9% 2.8% 13.3%
1 Year Return vs Industry and Market
  • ALRN underperformed the Biotechs industry which returned -1.3% over the past year.
  • ALRN underperformed the Market in United States of America which returned -15.9% over the past year.
Price Volatility
ALRN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aileron Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aileron Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $0.313301.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aileron Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aileron Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ALRN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.20
NasdaqCM:ALRN Share Price ** NasdaqCM (2020-04-03) in USD $0.31
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.72x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aileron Therapeutics.

NasdaqCM:ALRN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ALRN Share Price ÷ EPS (both in USD)

= 0.31 ÷ -1.20

-0.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aileron Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Aileron Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aileron Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:ALRN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
19.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.8x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.88x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aileron Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aileron Therapeutics's assets?
Raw Data
NasdaqCM:ALRN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.58
NasdaqCM:ALRN Share Price * NasdaqCM (2020-04-03) in USD $0.31
United States of America Biotechs Industry PB Ratio Median Figure of 430 Publicly-Listed Biotechs Companies 2.46x
United States of America Market PB Ratio Median Figure of 5,146 Publicly-Listed Companies 1.2x
NasdaqCM:ALRN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ALRN Share Price ÷ Book Value per Share (both in USD)

= 0.31 ÷ 0.58

0.54x

* Primary Listing of Aileron Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aileron Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Aileron Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aileron Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aileron Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aileron Therapeutics expected to grow at an attractive rate?
  • Aileron Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Aileron Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Aileron Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ALRN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:ALRN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 19.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ALRN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ALRN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 18 16 3
2023-12-31 6 -44 -22 4
2022-12-31 1 -26 -23 4
2021-12-31 0 -25 -19 4
2020-12-31 0 -24 -20 4
2020-04-05
NasdaqCM:ALRN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -26 -29
2019-09-30 -27 -29
2019-06-30 -27 -29
2019-03-31 -28 -31
2018-12-31 -28 -32
2018-09-30 -27 -31
2018-06-30 -25 -30
2018-03-31 -22 -26
2017-12-31 -21 -23
2017-09-30 -19 -20
2017-06-30 -18 -18
2017-03-31 -17 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aileron Therapeutics's earnings are expected to grow by 19.5% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Aileron Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ALRN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Aileron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ALRN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.26 0.26 0.26 1.00
2023-12-31 -0.43 -0.23 -0.63 2.00
2022-12-31 -0.49 -0.34 -0.59 3.00
2021-12-31 -0.49 -0.36 -0.74 3.00
2020-12-31 -0.65 -0.55 -0.83 3.00
2020-04-05
NasdaqCM:ALRN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.20
2019-09-30 -1.37
2019-06-30 -1.61
2019-03-31 -2.11
2018-12-31 -2.14
2018-09-30 -2.13
2018-06-30 -2.07
2018-03-31 -2.33
2017-12-31 -3.04
2017-09-30 -5.26
2017-06-30 -41.73
2017-03-31 -43.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aileron Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aileron Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aileron Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aileron Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aileron Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aileron Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aileron Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aileron Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aileron Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aileron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ALRN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -29.37 12.29 17.66
2019-09-30 -29.17 12.68
2019-06-30 -28.85 11.31
2019-03-31 -31.17 12.58
2018-12-31 -31.55 12.35
2018-09-30 -31.38 12.06
2018-06-30 -30.20 12.59
2018-03-31 -25.66 10.04
2017-12-31 -22.65 8.77
2017-09-30 -20.24 7.40
2017-06-30 -18.22 6.42
2017-03-31 -18.83 8.09
2016-12-31 -18.20 7.89
2016-09-30 -17.06 7.82
2016-06-30 -16.04 7.62
2016-03-31 -13.69 5.33
2015-12-31 -12.95 5.06
2015-09-30 -13.00 5.43
2015-06-30 -13.14 5.74
2015-03-31 -14.60 6.22
2014-12-31 -16.07 6.70
2013-12-31 22.35 0.19 6.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aileron Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aileron Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aileron Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aileron Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aileron Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aileron Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aileron Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aileron Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aileron Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aileron Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Aileron Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aileron Therapeutics Company Filings, last reported 3 months ago.

NasdaqCM:ALRN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 16.05 0.00 18.28
2019-09-30 22.82 0.00 24.56
2019-06-30 29.98 0.00 31.52
2019-03-31 12.85 0.00 13.27
2018-12-31 19.60 0.00 20.70
2018-09-30 26.03 0.00 27.95
2018-06-30 32.87 0.00 35.79
2018-03-31 40.98 0.00 43.29
2017-12-31 47.80 0.00 50.75
2017-09-30 54.01 0.00 56.87
2017-06-30 9.63 0.00 11.34
2017-03-31 14.28 0.00 15.29
2016-12-31 17.94 0.00 20.72
2016-09-30
2016-06-30
2016-03-31 3.36 0.00 3.77
2015-12-31 3.36 0.00 3.77
2015-09-30 6.48 0.00 7.77
2015-06-30 9.49 0.00 10.56
2015-03-31 9.49 0.00 10.56
2014-12-31 15.57 0.00 16.22
2013-12-31 11.51 0.00 14.07
  • Aileron Therapeutics has no debt.
  • Aileron Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aileron Therapeutics has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Aileron Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Aileron Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aileron Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aileron Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aileron Therapeutics dividends.
If you bought $2,000 of Aileron Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aileron Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aileron Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ALRN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1936 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ALRN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aileron Therapeutics has not reported any payouts.
  • Unable to verify if Aileron Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aileron Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aileron Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aileron Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aileron Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aileron Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aileron Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alves Aivado
COMPENSATION $1,463,705
AGE 49
TENURE AS CEO 1.6 years
CEO Bio

Dr. Manuel C. Aivado, also known as Alves, M.D., Ph.D., has been President, Chief Executive Officer and Director of Aileron Therapeutics, Inc. since September 6, 2018. Dr. Aivado served as Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Aileron Therapeutics, Inc. since September 2014 until September 6, 2018. Dr. Aivado served as Vice President of Clinical Development & Pharmacovigilance at Taiho Oncology, Inc. from March 2012 to September 2014. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, Inc., including as Senior Medical Director in the Clinical Development group from October 2006 to March 2012, where he was involved in numerous drug programs including ofatumumab (Arzerra(R)), trametinib (Mekinist(R)), pazopanib (Votrient(R)), and eltrombopag (Promacta(R)). Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for ten years. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado's work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. He is a German Board-certified physician for Internal Medicine, Hematology and Medical Oncology. Dr. Aivado received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.

CEO Compensation
  • Alves's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Alves's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Aileron Therapeutics management team in years:

1.4
Average Tenure
50
Average Age
  • The average tenure for the Aileron Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Alves Aivado

TITLE
President
COMPENSATION
$1M
AGE
49
TENURE
1.6 yrs

Vojo Vukovic

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$760K
AGE
52
TENURE
1.4 yrs

Rick Wanstall

TITLE
SVP, CFO & Treasurer
AGE
50
TENURE
0.6 yrs

D. Annis

TITLE
Senior Vice President of Research
AGE
46
TENURE
1.4 yrs

Kathryn Gregory

TITLE
Senior VP & Chief Business Officer
AGE
57
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Aileron Therapeutics board of directors in years:

1.8
Average Tenure
60.5
Average Age
  • The average tenure for the Aileron Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jeff Bailey

TITLE
Chairman of the Board
COMPENSATION
$214K
AGE
56
TENURE
2.1 yrs

Alves Aivado

TITLE
President
COMPENSATION
$1M
AGE
49
TENURE
1.6 yrs

Mike Kastan

TITLE
Chairman of Scientific Advisory Board

Loren Walensky

TITLE
Chairman of Scientific Advisory Board

Reinhard Ambros

TITLE
Lead Director
COMPENSATION
$109K
AGE
64
TENURE
2.1 yrs

Bill McKee

TITLE
Director
AGE
57
TENURE
0.8 yrs

Josef von Rickenbach

TITLE
Director
AGE
64
TENURE
0.8 yrs

David Nathan

TITLE
Member of Advisory Board
TENURE
12.5 yrs

Stephen Fesik

TITLE
Member of Advisory Board
AGE
65

Robert Grubbs

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Mar 20 Sell Novartis Venture Funds Company 18. Feb 20 11. Mar 20 -177,348 $0.72 $-111,541
14. Feb 20 Sell S.R. One, Limited Company 28. May 19 05. Jun 19 -926,593 $1.02 $-896,475
18. Nov 19 Buy Jeffrey Bailey Individual 14. Nov 19 15. Nov 19 55,000 $0.51 $28,050
14. Nov 19 Buy Jeffrey Bailey Individual 12. Nov 19 12. Nov 19 19,894 $0.53 $10,544
16. Sep 19 Buy Josef von Rickenbach Individual 12. Sep 19 13. Sep 19 113,145 $0.98 $110,505
05. Sep 19 Buy Josef von Rickenbach Individual 04. Sep 19 04. Sep 19 23,225 $0.71 $16,583
04. Sep 19 Buy Josef von Rickenbach Individual 30. Aug 19 03. Sep 19 28,466 $0.73 $20,396
03. Sep 19 Buy Josef von Rickenbach Individual 29. Aug 19 29. Aug 19 3,600 $0.77 $2,771
15. Aug 19 Buy Kathryn Gregory Individual 13. Aug 19 13. Aug 19 45,000 $0.65 $29,025
20. Aug 19 Buy Vojislav Vukovic Individual 16. Aug 19 16. Aug 19 75,000 $0.59 $44,453
X
Management checks
We assess Aileron Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aileron Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.

Details
Name: Aileron Therapeutics, Inc.
ALRN
Exchange: NasdaqCM
Founded: 2001
$8,713,012
27,810,358
Website: http://www.aileronrx.com
Address: Aileron Therapeutics, Inc.
490 Arsenal Way,
Suite 210,
Watertown,
Massachusetts, 02472,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ALRN Common Stock Nasdaq Capital Market US USD 29. Jun 2017
DB 015 Common Stock Deutsche Boerse AG DE EUR 29. Jun 2017
Number of employees
Current staff
Staff numbers
23
Aileron Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 08:06
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.